Butt JH, Docherty KF, Petrie MC, et al. - Researchers performed comparison of the efficacy and safety of dapagliflozin vs placebo in men and women with heart failure (HF) with reduced ejection fraction (HFrEF) enrolled in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). This is a prespecified subgroup analysis of a randomized clinical trial that included 4,744 patients. Outcomes revealed correlation of providing dapagliflozin vs placebo with an increase in the proportion of patients with an improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score, clinical summary score, and overall summary score and decrease in the proportion with a deterioration; this was observed regardless of gender. Men and women with HFrEF had similarly reduced risk of worsening heart failure and death and improved symptoms, physical function, and health-related quality of life in correlation with receiving dapagliflozin. Dapagliflozin was also safe and well-tolerated regardless of sex.